Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901100 | 1.00 | MAPK1 (0.52) | MAPK1MAPT | |
| SCHEMBL12285564 | 1.00 | MAPK1 (0.52) | MAPK1MAPT | |
| SCHEMBL12858723 | 0.85 | MAPK1 (0.60) | MAPK1 | |
| SCHEMBL16015886 | 0.79 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL598223 | 0.79 | ALDH1A1 (0.38) | MAPK1 | |
| SCHEMBL13038568 | 0.79 | MAPK1 (0.48) | MAPK1 | |
| SCHEMBL12980342 | 0.77 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL25070900 | 0.76 | — | — | |
| SCHEMBL13349789 | 0.76 | — | — | |
| SCHEMBL11375829 | 0.76 | MAPK1 (0.50) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-9388112-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-12 | — | — | US | disclosed |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-09-04 | — | — | US | disclosed |
| US-20130131167-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-23 | — | — | US | disclosed |
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | SHBG, KLK3, HSD17B11 | MAPK1 3831/4885MAPT 1962/4885 |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | AR, SHBG, ESRRA | MAPK1 4052/4885MAPT 3368/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | MAPK1 81/4885MAPT 2866/4885 |
| US-20130131167-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | CYP19A1, AR, SHBG | MAPK1 859/4885MAPT 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.